Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
27 hedge funds and large institutions have $392K invested in Navidea Biopharmaceuticals Inc. in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 25 closing their positions.
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
45% less funds holding
Funds holding: 49 → 27 (-22)
73% less capital invested
Capital invested by funds: $1.43M → $392K (-$1.04M)
84% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 25
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $14K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$144K |
| 2 |
VF
Virtu Financial
New York
|
+$107K |
| 3 |
Jane Street
New York
|
+$37.8K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$25.5K |
| 5 |
ACM
Allred Capital Management
Dallas,
Texas
|
+$13.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$38.2K |
| 2 |
Bank of New York Mellon
New York
|
-$19K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$16K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$16K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$12K |
NAVB Hedge Fund Activity: Q2 2019 in Review
27 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q2 2019, worth a combined $392K — down 73% from $1.43M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of NAVB and 4 opened new positions — a net loss of 21 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Wedbush Securities, adding an estimated $144K. The largest seller was Vanguard Group, cutting an estimated $38.2K.
- 27 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q2 2019, down from 49 in Q1 2019.
- Funds reported $392K of Navidea Biopharmaceuticals Inc. stock for Q2 2019, down 73% quarter-over-quarter.
- 4 funds opened new Navidea Biopharmaceuticals Inc. positions in Q2 2019 and 25 closed out, a net change of -21 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q2 2019 was Wedbush Securities, an estimated $144K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q2 2019 was Vanguard Group, an estimated $38.2K sold.
Based on aggregated 13F filings for Q2 2019.